Purpose: Everolimus inhibits mTOR, a component of PI3K/AKT pro-survival signaling triggered by MYD88 and CXCR4 activating mutations in Waldenstrom's Macroglobulinemia (WM).
Introduction
The PI3K/AKT pathway is an important survival signaling cascade that supports the growth and survival of malignant lymphoplasmacytic cells (LPC) in Waldenstrom Macroglobulinemia (WM). 1 Activating mutations in MYD88 and CXCR4, found in 95% and 30% of WM patients, respectively, trigger PI3K/AKT signaling. [2] [3] [4] [5] Everolimus is an orally administered inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase that is downstream of the PI3K/AKT signaling pathway. 6 Everolimus is approved by the U.S. Food and Drug Administration for treatment of several solid malignancy indications, and shows in vitro activity against WM cells. 6 In previous work, we evaluated the activity of everolimus in previously treated WM patients. 7 The overall response rate (ORR) using consensus criteria was 73%, and 50% of patients achieved a major response. 8 The median progression-free survival (PFS) was 21 months in this study. 9 Toxicities were common, with grade 3 or higher adverse events observed in 67% of patients. 8, 9 We therefore examined the safety and efficacy of everolimus in previously untreated, symptomatic WM patients. We performed serial bone marrow (BM) biopsies to more fully delineate the impact of therapy on WM disease burden, and also assessed the impact of MYD88 and CXCR4 mutations on treatment outcome. We present herein the first report from this prospective, multicenter study.
Patients and Methods
Symptomatic WM patients requiring therapy based on consensus recommendations, 10 and who were previously untreated were eligible to enroll.
To meet eligibility, patients must have had a platelet count of ≥75 x 10 
Statistical analysis
The primary endpoint was determination of overall response rate. Response determinations were made using consensus criteria adapted from the Sixth International Workshop on WM.
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Secondary endpoints included determination of time to progression, and assessment of safety and tolerability of everolimus.
Sample size was predicated on an expected overall response rate of >70%, and a minimal acceptable response rate of 50% based on assumptions derived from our previous published experience with everolimus. 8, 9 PFS was defined as the time between initiation of therapy and date of progression, death or last followup. Patients without disease progression (including those taken off study for toxicity) were censored at the date of their last evaluation. For categorical univariate analyses, the Kaplan-Meier method for incomplete observations was used to estimate PFS curves, which were compared using the log-rank test. A Wilcoxon Rank-Sum test was used for analysis of pre-and post-therapy continuous variables. For categorical variables, a two-tailed Fisher's exact test was used. P-values <0.05 were considered statistically significant. All graphics and calculations were obtained using STATA 13.1 (StataCorp LP, College Station, TX, USA).
Patients and disease characteristics
Thirty-three patients were enrolled, and their baseline characteristics are shown in Table 1 respectively (p=0.56). Among responders, the median time to at least a minor response was 1 month (range 1-9 months), while the median time to a major response was 2 months (range 1-27 months).
Time to progression
With a median follow-up of 13.1 months (range 1.6-64.6 months), all patients were alive. All patients are off treatment. The Kaplan-Meier curve for PFS for all patients appears in Figure 2 . The median time to progression was 21 months (95% CI 11-39 months). By univariate analysis, neither baseline BM disease burden >50% versus <50% (p=0.95), serum IgM >4,000 versus <4,000 mg/dL (p=0.59), nor hemoglobin >11 versus <11 g/dL (p=0.16) levels were associated with increased risk for progression. Dose de-escalation (<10 mg/day versus 10 mg/day) was also not associated increased risk of progression (p=0.34).
Categorical response attainment was associated with progression risk. Patients achieving a PR or better had a longer PFS versus those with less than a PR (33 versus 5 months, respectively; HR=4.350, 95% CI 3.9-113 months, p=0.0011).
Toxicities
Grade 2 or higher toxicities that were at least possibly related to protocol therapy are presented in Table 2 . The most common non-hematological treatment related Grade >2 toxicities included mucositis (27.3%), infection (21.2%), rash (21.2%), fatigue (18.2%), and pneumonitis (18.2%). Treatment related hematological toxicities that were at least grade >2 included anemia (27.3%), neutropenia (18.2%), and thrombocytopenia (15.2%). Dose reduction due to adverse events occurred in 9 patients, with dose reduction to 7.5 mg (N=5) and 5.0 mg (N=2) daily, and 5.0 mg (N=2) every other day. Treatment was discontinued in 32 patients, with reasons for discontinuation as follows: nonresponse (n=6); progressive disease (n=15); pneumonitis (n=5); withdrawal of consent (N=3) that included one patient for recurring grade 2 stomatitis; noncompliance (N=2), and prolonged study drug hold for unrelated infection.
Following discontinuation of everolimus, rapid increases in serum IgM levels were common. In seven patients, serum IgM levels showed at least a doubling.
In these patients, serum IgM levels increased from a median of 1,410 (range 306-2,880 mg/dL) to 4,670 (range 2,510-5,910 mg/dL) at a median of 39 days (range 18-95 days) following discontinuation of everolimus. Four of these patients underwent plasmapheresis, including two for symptomatic hyperviscosity, and two to prevent a rituximab-related IgM flare with subsequent therapy.
IgA and IgG hypogammaglobulinemia
At baseline, median serum IgA and IgG levels were 99 and 884 mg/dL, respectively. Following therapy, at last individual patient assessment, median serum IgA and IgG levels declined to 44 and 447 mg/dL, respectively (p=0.49 and p=0.23, respectively).
Discussion
In this prospective, multicenter study, we examined the single agent activity of everolimus in symptomatic, untreated WM patients. Everolimus inhibits mTOR, a serine-threonine kinase that contributes to PI3K/AKT directed growth and survival signaling in WM. 6, 7 Activating mutations in both MYD88 and CXCR4 trigger PI3K/AKT signaling. 1, 2 Our findings showed that everolimus was associated with overall and major responses in 72.7% and 60.6%, respectively, using consensus criteria. 11 However, the frequent finding of IgM discordance complicated response interpretation since consensus criteria for response in WM primarily rely on changes in serum IgM levels. IgM discordance has been observed with other therapeutics used to treat WM patients including rituximab and ofatumumab that can increase, while bortezomib and ibrutinib can decrease serum IgM levels independent of changes in BM tumor burden. [13] [14] [15] [16] [17] A bystander effect for the "IgM flare" by rituximab has been proposed wherein immune cells release IL-6 though interactions with the Fc domain of rituximab prompting IgM release by WM cells. 18 The BTK substrate STAT5A regulates IgM secretion in WM cells, and its selective inhibition by ibrutinib has been proposed to contribute to its discordant findings. 17 However, the PI3K/AKT pathway is not a known contributor to STAT5A signaling, and other on-target signaling events, as well as off-target effects that contribute to IgM production and secretion could be impacted by everolimus.
The impact of MYD88 and CXCR4 mutations on response activity was also investigated. Genotyping was performed for 21 patients (all at DFCI). While the study numbers are small for a meaningful analysis, the one patient with MYD88 wild-type was a non-responder, while the overall and major response rates were lower in CXCR4 mutated patients. Wild-type MYD88 and CXCR4 WHIM mutation status were also associated with lower overall and major clinical responses to ibrutinib. and/or CXCR4 activating mutations that include canonical NFkB, PI3K/AKT and MAPK/ERK signaling. 4, 5 Drug related toxicity was responsible for discontinuation of everolimus in 9 (27%) patients, including 5 for pneumonitis. In total, 6 (18%) patients experienced treatment related pneumonitis that resulted in hospitalization for 3 patients. The incidence of grade 2 or higher treatment related pneumonitis was higher in this study versus that observed by us in our study with everolimus monotherapy in previously treated WM patients (18% versus 8%). Treatment related pneumonitis has also been reported with idelalisib, and may represent a class effect for therapeutics that target PI3K/AKT signaling. A higher incidence of autoimmune related events, including pneumonitis has also been observed with idelalisib in frontline versus previously treated CLL patients. 20 The impact of previous treatment status on T-reg immune cell function may have contributed for differences in autoimmune activity between frontline and previously treated patients exposed to idelalisib, and may be relevant in WM patients undergoing everolimus therapy. 20 Steroids were effective in the treatment of everolimus related pneumonitis, which resolved in all patients. Oral mucositis, a known side effect of everolimus, was less pronounced (no grade >3 events) in this study compared to our experience in previously treated patients, and likely reflected the routine use of an oral swish and spit dexamethasone solution during the first three months of everolimus therapy as a preventative. Despite this measure, mucositis occurred at a grade 2 level in 27% of patients, and contributed to early study withdrawal for one patient. Minimal systemic steroid absorption was likely associated with the oral swish and spit dexamethasone solution. Cytopenias were also commonly observed adverse events, particularly grade 2 or higher anemia that was seen in 27% of patients.
The study findings show that everolimus is active in previously untreated WM patients. Discordance between serum IgM levels and BM disease burden is remarkable, and cessation of everolimus can produce rapid rebounds in serum IgM levels. Toxicity resulted in premature discontinuation of therapy in 27% of patients, and included pneumonitis that appeared more common in this study compared to our experience in previously treated WM patients. The risks and benefits of everolimus should carefully be weighed against other available treatment options for the primary therapy of WM. Current NCCN and WM consensus guidelines support use of everolimus in relapsed/refractory WM disease, and appear reasonable in view of the risk/benefit identified for everolimus in this frontline study. 
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